CRP and COVID-19: Although further investigations are needed to determine how type I interferon-neutralizing antibodies contribute to the elevated IFN-reactive protein (CRP) and D-dimer levels in COVID-19 patients, the likely mechanism is as follows: the presence of such neutralizing antibodies undermines the ability of host innate immunity to restrain SARS-CoV-2 infection, leading to uncontrolled spread of the virus and consequently more extensive tissue damage and elevated inflammation.